Related Experiment Video
Updated: May 21, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
Intrathecal chemotherapy neurotoxicity: unveiling the challenges of diagnosis, management, and prevention
Ali H Algiraigri1,2,3, Wasil Jastaniah3
1Department of Hematology, Faculty of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Abstract:
Intrathecal (IT) chemotherapy is a highly effective treatment and prophylaxis for central nervous system (CNS) involvement in leukemia and lymphoma. Despite its therapeutic efficacy, IT chemotherapy has potential neurotoxicity risks, including acute and delayed symptoms that can severely affect patient outcomes. Effective management of acute, IT-related neurotoxicity requires a prompt, case-specific approach that considers symptom severity, the type of chemotherapeutic agent, and individual patient factors. This review examines a case-based approach to managing common scenarios of IT neurotoxicity and provides a structured guide for clinicians in assessing and addressing these complications.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

